Malta - English - Medicines Authority

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - inactivated strain, flury lep - solution for injection - inactivated strain flury lep 100 iu/ml - immune sera and immunoglobulins

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines gmbh - rabies virus (flury lep) inactivated - infus/pdr/oral soln - >= 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines gmbh - inactivated rabies virus - powder and solvent for solution for injection - 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus

United States - English - NLM (National Library of Medicine)

gsk vaccines gmbh - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

United States - English - NLM (National Library of Medicine)

a-s medication solutions - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

Singapore - English - HSA (Health Sciences Authority)

aenon pharmaceuticals sea pte. ltd. - inactivated rabies virus (strain flury lep) - injection, powder, lyophilized, for solution - potency≥2.5iu - inactivated rabies virus (strain flury lep) potency≥2.5iu

United States - English - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually an immunization series is initiated and completed with 1 vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv.4,11 preexposure vaccination: see table 1 and dosage and administration. preexposure vaccination consists of 3 doses of rabavert 1.0 ml given intramuscularly (deltoid region), 1 each on days 0, 7, and 21 or 281 (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see dosage and administration: postexposure prophylaxis of previously im

Kenya - English - Pharmacy and Poisons Board

bilthoven biologicals b.v antonie van leeuwenhoeklaan 9-13, bilthoven, 3721 - inactivated poliomyelitis virus type 1… - suspension for injection - inactivated poliomyelitis virus type 1 -40… - viral vaccines: poliomyelitis vaccines

Kenya - English - Pharmacy and Poisons Board

inactivated rabies vaccine - injection - inactivated rabies vaccine - antibacterials for systemic use

Canada - English - Health Canada

bavarian nordic as - inactivated rabies virus (flury lep) - powder for solution - 2.5unit - inactivated rabies virus (flury lep) 2.5unit - vaccines